Memantine ER/Donepezil: A Review in Alzheimer's Disease

CNS Drugs

Volumn 29, Issue 11, 2015, Pages 963-970

  Greig, Sarah L ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL PLUS MEMANTINE; DRUG COMBINATION; MEMANTINE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE;

ADVERSE OUTCOME; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFICACY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); DRUG COMBINATION;

ALZHEIMER DISEASE; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG COMBINATIONS; HUMANS; MEMANTINE; NOOTROPIC AGENTS; PIPERIDINES;

EID: 84947917035     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-015-0287-2     Document Type: Article

References (24)

1. Association Alzheimer's. 2014 Alzheimer's disease facts and figures. Alzheimers Dement. 2014;10(2):e47-92.
2. Atri A. Effective pharmacological management of Alzheimer's disease. Am J Manag Care. 2011;17(Suppl 13):S346-55.
3. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317-24.
4. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012;366(10):893-903.
5. Hendrix S, Ellison N, Stanworth S, et al. Post hoc evidence for an additive effect of memantine and donepezil: consistent findings from DOMINO-AD study and memantine clinical trial program. J Prev Alzheimers Dis. 2015;2(3):165-71.
6. Schmidt R, Hofer E, Bouwman FH, et al. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. Eur J Neurol. 2015;22(6):889-98.
7. Atri A, Molinuevo JL, Lemming O, et al. Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther. 2013;5(1):[article no. 6].
8. Atri A, Shaughnessy LW, Locascio JJ, et al. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22(3):209-21.
9. Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80(6):600-7.
10. Plosker GL. Memantine extended release (28 mg once daily): a review of its use in Alzheimer's disease. Drugs. 2015;75(8):887-97.
11. Forest Pharmaceuticals Inc. Namzaric™ (memantine hydrochloride extended-release and donepezil hydrochloride) capsules, for oral use: US prescribing information. 2014. http://www.fda.gov. Accessed 14 Oct 2015.
12. Parsons CG, Danysz W, Dekundy A, et al. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease. Neurotox Res. 2013;24(3):358-69.
13. Jelic V, Darreh-Shori T. Donepezil: a review of pharmacological characteristics and role in the management of Alzheimer disease. Clin Med Insights Ther. 2010;2:771-88.
14. Boinpally R, Chen L, Zukin SR, et al. A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer's disease: two phase I studies in healthy volunteers. Clin Drug Investig. 2015;35(7):427-35.
15. Grossberg GT, Manes F, Allegri RF, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs. 2013;27(6):469-78.
16. Grossberg GT, Alva G, Hendrix S, et al. Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial [abstract no. P1-370 plus poster]. Alzheimers Dement. 2014;10(4 Suppl):P450.
17. Atri A, Hendrix SB, Pejovic V, et al. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis. Alzheimers Res Ther. 2015;7(1):[article no. 28].
18. Hendrix S, Ellison N, Otcheretko V. Complementary benefit of memantine and donepezil on activities of daily living by disease stage when used together: post hoc analysis of two trials in moderate to severe Alzheimer's disease [abstract no. 2710 plus poster]. In: Alzheimer's Association International Conference. 2015.
19. Atri A, Hendrix S, Ellison N, et al. Caregiver distress related to neuropsychiatric symptoms is reduced with extended-release memantine-cholinesterase inhibitor combination in patients with moderate to severe Alzheimer's disease [abstract no. 4636 plus poster]. In: Alzheimer's Association International Conference. 2015.
20. Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148(5):370-8.
21. Rountree SD, Chan W, Pavlik VN, et al. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther. 2009;1(2):[article no. 7].
22. Borah B, Sacco P, Zarotsky V. Predictors of adherence among Alzheimer's disease patients receiving oral therapy. Curr Med Res Opin. 2010;26(8):1957-65.
23. Brewer L, Bennett K, McGreevy C, et al. A population-based study of dosing and persistence with anti-dementia medications. Eur J Clin Pharmacol. 2013;69(7):1467-75.
24. Saint-Laurent Thibault C, Stillman IO, Chen S, et al. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the United States. J Med Econ. 2015. doi: 10.3111/13696998.2015.1063501.